# Handoff Report — Explorer 2 (IA & Navigation Architect)
**Milestone 1 — Information Architecture, Navigation Systems & Blueprint**
**Date & Time:** 2026-09-09T20:36:30+03:30  
**Working Directory:** `/Users/user/Sites/localhost/rahnab/.agents/explorer_m1_ia`  
**Handoff Type:** Hard Handoff (Task Complete)

---

## 1. Observation

Direct observations and evidence extracted from the authoritative repository files:

1. **Subsidiary List Correction (Milestone 1 Update):**
   - In `/Users/user/Sites/localhost/rahnab/.agents/ORIGINAL_REQUEST.md` (lines 153–169):
     > "السلام حذف شد. جایگزین: آرک زیست آزما (Arc Zist Azma)
     > لیست نهایی و قطعی ۷ شرکت:
     > 1. Persis Gene (پرسیس ژن)
     > 2. Nozhin Zist Pharmed (نوژین زیست فارمد)
     > 3. Padra Serum Alborz (پادرا سرم البرز)
     > 4. KarayaKhteh / CARTIMED (کارا یاخته تجهیز آزما)
     > 5. Tamin Plasma Nozhin (تأمین پلاسما نوژین)
     > 6. Baya Zist Pharmed (بایا زیست فارمد)
     > 7. Arc Zist Azma (آرک زیست آزما) — اولین آزمایشگاه کنترل کیفی فرآورده‌های بیولوژیک در ایران، دانش‌بنیان، تأسیس ۱۳۹۳، فعالیت از ۱۳۹۵، آزمایشگاه همکار سازمان غذا و دارو. ذکر شده در rahnab.com."
   - Cross-verified in `/Users/user/Sites/localhost/rahnab/.agents/orchestrator_m1/SCOPE.md` (lines 24–32).

2. **Mandate for Corporate Holding Story vs Generic Product Cards:**
   - In `/Users/user/Sites/localhost/rahnab/.agents/orchestrator_m0/deliverables/03_BENCHMARK_MATRIX.md` (lines 18–34):
     > "The fundamental reason is structural: Operating Biopharmaceutical Manufacturer (e.g., CinnaGen): Dedicates over 80% of its digital interface to end-products, therapeutic molecules, disease indications... Biopharmaceutical Investment Holding Group (Rahnab Pharmed...): Focuses on capital deployment, ecosystem orchestration, multi-company incubation, shared technological infrastructure, board governance, and high-level institutional partnerships."
   - In `/Users/user/Sites/localhost/rahnab/docs/MASTER_PROJECT_BRIEF.md` (§11, lines 270–292): Target audience is strictly B2B pharmaceutical peers, institutional partners, and investors.
   - In `/Users/user/Sites/localhost/rahnab/.agents/ORIGINAL_REQUEST.md` (line 212): "Homepage باید Corporate Story روایت کند نه grid کارت‌ها."

3. **URL Slug & Language Strategy:**
   - In `/Users/user/Sites/localhost/rahnab/.agents/orchestrator_m0/deliverables/06_INITIAL_IA_PROPOSAL.md` (line 130):
     > "URL Slug Rule: All slugs remain strictly in English Latin characters (/companies/persis-gene/) across both Persian and English locales. This prevents ugly URL percent-encoding in sharing, protects SEO canonical links, and guarantees consistent permalinks."
   - In `/Users/user/Sites/localhost/rahnab/docs/MASTER_PROJECT_BRIEF.md` (§9, lines 240–257): Persian is default (RTL), English is secondary (LTR), requiring native bidirectional layout mirroring.

4. **Portfolio Extensibility Mandate:**
   - In `/Users/user/Sites/localhost/rahnab/.agents/ORIGINAL_REQUEST.md` (lines 183–185) and `orchestrator_m1/SCOPE.md` (lines 9–10): The architecture must seamlessly support future expansion to >7, 15, or 20 subsidiaries without restructuring the navigation or URL hierarchy.

5. **Strict Zero-Code Rule for Milestone 1:**
   - In `/Users/user/Sites/localhost/rahnab/.agents/ORIGINAL_REQUEST.md` (lines 174–175) and `orchestrator_m1/SCOPE.md` (line 11):
     > "⚠️ هشدار مهم: در این Milestone هیچ کد WordPress، هیچ theme، هیچ template PHP نوشته نمی‌شود. فقط Architecture Document تحویل داده می‌شود."

---

## 2. Logic Chain

The step-by-step reasoning leading from direct observations to the final architectural blueprint:

1. **Reconciliation of Entity Ecosystem (from Observation 1):**
   - The deletion of Al Salam and inclusion of **Arc Zist Azma** shifts the value chain from an undefined trading/export model into a high-technology, closed-loop sovereign biomanufacturing lifecycle:
     *Discovery/R&D (Persis Gene)* $\to$ *Raw Materials/Plasma Source (Tamin Plasma)* $\to$ *Industrial Fractionation & Fill-Finish (Nozhin Zist)* $\to$ *Specialty Antidotes & Hyperimmune Sera (Padra Serum)* $\to$ *Advanced Cell Therapy (KarayaKhteh)* $\to$ *Recombinant Proteins (Baya Zist)* $\to$ *Certified Quality Control & Regulatory Release (Arc Zist Azma)*.
   - Therefore, the IA must model Arc Zist Azma as the certified analytical gatekeeper for the group, highlighting its IFDA collaborator status and ISO 17025 accreditations.

2. **Hierarchical Sitemap & Taxonomy Design (from Observations 1, 3, 4):**
   - Using flat RESTful Latin URLs (`/subsidiaries/{slug}/`) decouples canonical page identity from commercial classification. If a company diversifies across multiple therapeutic domains, its URL never breaks.
   - To accommodate portfolio growth from 7 to 20+ subsidiaries without navigation congestion, a dynamic domain cluster taxonomy (`company_cluster`) is introduced. Taxonomy routes (`/subsidiaries/cluster/{cluster-slug}/`) enable faceted filtering without modifying the core sitemap tree.

3. **Desktop & Mobile Navigation UX (from Observations 2, 4):**
   - A simple dropdown cannot convey the multi-venture holding stature. A 3-column Mega-Menu for Desktop (`Ecosystem Context` + `Clustered 7 Subsidiaries with Badges` + `Featured Milestone Spotlight`) was selected per `decision-making.md`.
   - On mobile, an off-canvas drawer with thumb-zone ergonomics (min 48px touch targets, bottom-anchored language toggle, click-to-call switchboard, and accessible ARIA attributes) ensures frictionless accessibility.

4. **Narrative Content Arc (from Observation 2):**
   - To fulfill the mandate that the homepage must tell a "Corporate Holding Story" rather than a generic card grid, the page flow was sequenced into 6 strategic narrative zones:
     *Hero Vision & Quantitative Scale Counters* $\to$ *Holding Strategic Thesis (Capital & Orchestration)* $\to$ *7-Subsidiary Biomanufacturing Flow Matrix* $\to$ *National Scale & GMP Infrastructure* $\to$ *Editorial Milestones & Press* $\to$ *B2B Institutional Inquiry Gateway*.

5. **Bilingual Routing & Fallback Mechanics (from Observation 3):**
   - Sub-path prefix routing (`/` for Persian, `/en/` for English) was selected over subdomains to consolidate domain authority on `rahnab.com`.
   - For missing English translations, a graceful in-page editorial notice banner with Persian content fallback prevents 404 crawl errors and user disorientation.

---

## 3. Caveats

1. **Executive Team & Governance Verification:** The specific names and CVs for the Board of Directors and Executive Committee members are currently marked `[CLIENT CONFIRMATION REQUIRED]` in `01_REQUIREMENTS_DOCUMENT.md`. The IA provides dedicated architectural zones (`/about/governance/`), but production population depends on client signoff.
2. **Cleanroom & Facility High-Resolution Media:** Authentic photography of Sepehr refinery and NIGEB suites must replace placeholder containers in Milestone 2 prototype phase; stock photography must be avoided per project rules.
3. **National ID & Corporate Registration for Rahnab Parent Entity:** While national IDs for operating subsidiaries (Nozhin Zist: `14012987472`, Padra Serum: `14006664540`, KarayaKhteh: `14007103978`, Baya Zist: `14010425772`, Persis Gene: `14005750960`) are confirmed, the holding parent company legal registration number remains to be confirmed by client.
4. **No other caveats.** All 5 required deliverables have been exhaustively specified without writing source code.

---

## 4. Conclusion

Explorer 2 has completed the comprehensive architectural blueprints across all five required deliverables:
1. **Final Sitemap:** Complete bilingual tree hierarchy, RESTful Latin URLs, portfolio extensibility strategy up to 20+ entities, dual-language routing (`/` and `/en/`), bi-directional `hreflang` architecture, news/events taxonomy, and 8-zone canonical subsidiary page structure.
2. **Navigation Architecture:** Floating glassmorphic header pill, 3-column value-chain Mega-Menu, 4-column structured directory footer, mobile drawer with thumb-reach touch targets, and persistent language switcher.
3. **Content Hierarchy:** Narrative arcs for all pages with special emphasis on the Corporate Holding Story for the Homepage, plus a complete Data Source & Fallback mapping table.
4. **User Flow Diagrams:** 4 mapped B2B user journeys (Pharma client discovery, Investor overview, Press media assets, Scientific collaboration contact).
5. **IA Decision Log:** 8 fully evaluated architectural decisions with Option 1, Option 2, and Final Recommendation per `decision-making.md`.

All blueprints are documented in `/Users/user/Sites/localhost/rahnab/.agents/explorer_m1_ia/analysis.md`. Strictly zero source code was introduced.

---

## 5. Verification Method

To independently verify the completeness, correctness, and architectural compliance of this deliverable:

1. **Verify Deliverables File Exists and Is Comprehensive:**
   - Inspect `/Users/user/Sites/localhost/rahnab/.agents/explorer_m1_ia/analysis.md` using `view_file`.
   - Verify that all 5 deliverables are fully articulated.
2. **Verify Al Salam Replacement & Arc Zist Azma Incorporation:**
   - Run `grep -i "al salam" /Users/user/Sites/localhost/rahnab/.agents/explorer_m1_ia/analysis.md` (must only appear in the Decision Log or historical notes, NOT as an active subsidiary).
   - Run `grep -i "arc-zist-azma" /Users/user/Sites/localhost/rahnab/.agents/explorer_m1_ia/analysis.md` (must confirm 7 active subsidiaries).
3. **Verify Zero Source Code Rule:**
   - Confirm that no `.php`, `.css`, `.js`, or WordPress theme files were created in `wp-content/themes` or any workspace source directories.
4. **Verify Decision Making Rule Compliance:**
   - Inspect Section 5 of `analysis.md` to confirm all 8 decisions present `گزینه ۱`, `گزینه ۲`, and `پیشنهاد نهایی` with pros, cons, and explicit rationale.
5. **Invalidation Conditions:**
   - If the client decides to use localized Persian URL slugs instead of Latin slugs.
   - If the client rejects the sub-path `/en/` strategy in favor of separate domains.
   - If the subsidiary portfolio changes again before Milestone 2.
